A 52-year-old woman on long-term warfarin therapy (INR 3.2, target 2–3 for mechanical mitral valve) presents with recurrent bilateral epistaxis over the past 3 days. She denies trauma, nasal surgery, or prior epistaxis. Vital signs are stable. Anterior rhinoscopy shows mild mucosal edema and crusting but no active bleeding site. Which of the following is the MOST appropriate initial management?

Explanation

## Management of Anticoagulant-Related Epistaxis This patient has **recurrent epistaxis in the setting of therapeutic anticoagulation** — a common and manageable scenario that requires careful balancing of bleeding risk against thromboembolism risk. ### Clinical Context **High-Yield:** - INR 3.2 is **within target range** (2–3) for mechanical mitral valve; no over-anticoagulation. - **Bilateral epistaxis** suggests mucosal fragility from anticoagulation, not a structural lesion or local trauma. - Stable vital signs and no active bleeding on examination indicate **non-emergent, chronic epistaxis**. - Goal: Maintain anticoagulation for cardiac protection while preventing recurrent bleeds. ### Pathophysiology Anticoagulation (warfarin, DOACs, antiplatelet agents) impairs hemostasis and increases bleeding from minor mucosal trauma or drying. The nasal mucosa is particularly vulnerable due to: - Rich vascularization - Exposure to dry air and crusting - Frequent minor trauma from nose-blowing or rubbing ### Management Hierarchy for Anticoagulant-Related Epistaxis ```mermaid flowchart TD A[Anticoagulant-related epistaxis]:::outcome A --> B{Hemodynamically<br/>stable?}:::decision B -->|No| C[Reverse anticoagulation<br/>+ aggressive hemostasis]:::urgent B -->|Yes| D{Active bleeding<br/>on exam?}:::decision D -->|Yes| E[Topical hemostatics<br/>+ consider packing]:::action D -->|No| F[Optimize INR<br/>+ topical agents<br/>+ nasal hygiene]:::action E --> G[Monitor, maintain<br/>anticoagulation]:::action F --> G G --> H[Recurrent?]:::decision H -->|Yes| I[Endoscopy ±<br/>cautery/ligation]:::action H -->|No| J[Continue prophylaxis]:::action ``` ### Why Option 2 (Optimize INR + Topical Hemostatics + Nasal Hygiene) Is Correct **Key Point:** - This is a **stable, non-emergent epistaxis** in a patient with therapeutic anticoagulation. The goal is to **maintain cardiac protection** while reducing bleeding recurrence. **Rationale:** 1. **INR Optimization**: Reducing INR to 2–2.5 (lower end of therapeutic range) decreases bleeding risk without compromising thromboembolism protection for mechanical mitral valve. This is guideline-recommended for patients with recurrent bleeding on anticoagulation. 2. **Topical Hemostatic Agents**: - **Thrombin (topical)**: Directly activates fibrinogen to fibrin; effective for mucosal bleeding. - **Tranexamic acid (topical or systemic)**: Inhibits fibrinolysis; reduces epistaxis recurrence by ~50% in anticoagulated patients. - **Topical epinephrine or oxymetazoline**: Causes vasoconstriction; reduces bleeding without systemic absorption. 3. **Nasal Hygiene Counseling**: - Avoid nose-blowing, picking, or rubbing. - Use saline nasal irrigation to prevent crusting. - Apply petroleum jelly or antibiotic ointment to nasal vestibule to reduce drying. - Humidify bedroom air. **Clinical Pearl:** - Prophylactic topical hemostatics (thrombin, tranexamic acid) applied 2–3 times weekly can prevent recurrent epistaxis in anticoagulated patients without requiring anticoagulation reversal. ### Why Other Options Are Incorrect **Option 0: Immediate Reversal + Packing** - **Over-treatment** for a stable, non-emergent bleed. - Reversal of warfarin (FFP + vitamin K) carries significant **thromboembolism risk** in a patient with mechanical mitral valve; reversal should be reserved for life-threatening hemorrhage or INR >4. - Packing is not indicated without active bleeding on examination. - Risks sinusitis, aspiration, and patient morbidity. **Option 1: Reduce Warfarin + Decongestant + Follow-up** - **Inadequate management**: Reducing warfarin without topical hemostatics leaves the patient at risk for recurrent bleeding. - Topical decongestants (oxymetazoline) are short-acting and do not address underlying mucosal fragility. - Passive follow-up without active intervention is suboptimal. **Option 3: Discontinue Warfarin + Switch to Aspirin** - **Dangerous**: Discontinuing warfarin in a patient with mechanical mitral valve risks **acute thrombosis** and stroke (annual thromboembolism risk ~4–6% without anticoagulation). - Aspirin 75 mg is **inadequate anticoagulation** for mechanical valve and does not replace warfarin. - Requires urgent cardiology consultation and bridging anticoagulation (LMWH or UFH) if warfarin must be held. ### Summary Table: Epistaxis Management by Anticoagulation Status | Scenario | INR Status | Management | |----------|-----------|-------------| | **Stable, no active bleed** | Therapeutic | Optimize INR (lower end), topical hemostatics, nasal hygiene | | **Active bleeding, stable** | Therapeutic | Topical hemostatics, consider packing; maintain anticoagulation | | **Active bleeding, unstable** | Therapeutic | Reverse anticoagulation (FFP + vitamin K), aggressive hemostasis, ICU monitoring | | **Recurrent despite optimization** | Therapeutic | Endoscopy ± cautery/vessel ligation; maintain anticoagulation | | **Over-anticoagulation (INR >4)** | Supra-therapeutic | Reduce warfarin; vitamin K if INR >4; manage bleed as above |